Trial Profile
A phase II study of CCI-779 [temsirolimus] in patients with recurrent glioblastoma multiforme
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Biomarker; Therapeutic Use
- 24 Sep 2005 New trial record.